Services Improve the Information Available to Oncologists and Pathologists in Determining Patient Risk Profiles and Treatment
Diagnostic Industry Veteran Wayne Brinster Joins as CEO
PreciseDx, the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, announced that it has raised $10.75 million in Series A Preferred in 2021 funding to support the ongoing development and commercialization of its AI-powered risk stratification platform. Leveraging AI insights and data derived from high-volume, well-annotated study populations, PreciseDx offers breast cancer diagnostic test services, with a prostate cancer test in development. The use of morphology features to stratify cancer risk provides valuable insights into cancer treatment, attracting the attention of healthcare innovators. The Company also announced the appointment of industry veteran Wayne Brinster to Chief Executive Officer, which was effective September 2021. Brinster brings more than 30 years of executive leadership, product commercialization, and operations experience to the Company, including management positions at MedTest, Wheaton Industries / DWK, Synthon Pharmaceuticals, and Becton Dickinson.
The round was led by the Merck Global Health Innovation Fund (Merck GHI) with additional investment from a number of healthcare leaders and innovators, including Mount Sinai Health System, Agilent Technologies, IBM Ventures, and the Hobart Group. The funding will be used to support the development and commercialization of additional cancer diagnostics and clinical trial testing.
“I am excited to join PreciseDx at this important inflection point. PreciseDx was established to improve the quality of cancer treatment for all patients through our risk stratification platform. The level of patient-specific detail we can provide to oncologists and pathologists is compelling. The results we are seeing are so promising and risk stratification is so critical in selecting the proper cancer treatment that we are already attracting the attention of the healthcare industry,” said Brinster. “We are grateful for our investors and their support of the scientific excellence and research that has gone into our technology. We look forward to developing best-in-class tests and making them widely available.”
Based on research and technology developed at Mount Sinai, the PreciseDx Platform is the first risk stratification platform designed to leverage an AI-powered Morphology Feature Array to deliver patient-specific insights that aid in disease state characterization, enabling better treatment decisions and outcomes. Utilizing data derived from numerous studies, the PreciseDx Platform combines critical tissue-derived information with clinical data to create patient-specific risk profiles with predicted outcomes, assigned risk for disease progression and recurrence, and recommendations for patient management.
“Merck GHI is excited to support PreciseDx as they help accelerate the digitization of pathology,” said David M. Rubin, Ph.D., Managing Director, Merck GHI. “AI-enabled, personalized healthcare is the future. We believe the ability to create and leverage billions of novel data points has the potential to truly change cancer treatment.”
PreciseDx has a mission to improve cancer treatment and outcomes through data-driven, patient-specific pathology information unavailable through other means. Today, breast cancer accounts for more than 40,000 deaths each year. Globally, about 1 in 6 deaths is due to cancer.
“We look forward to working with PreciseDx as it aims to advance the cancer risk stratification technology to patients and society,” said Erik Lium, PhD, President, Mount Sinai Innovation Partners and Executive Vice President and Chief Commercial Innovation Officer, Mount Sinai Health System.
The cancer risk stratification technology above is based on intellectual property developed by Mount Sinai faculty and. Licensed to PreciseDx. Mount Sinai and Mount Sinai faculty have a financial interest in PreciseDx. Mount Sinai also has representation on the PreciseDx Board of Directors, including Dr. Erik Lium.
Recommended AI News: Direct Fiat On-Ramps Come to Algorand (ALGO) via Alchemy Pay (ACH)
[To share your insights with us, please write to email@example.com]
The post PreciseDx Raises $10.75 Million Series A Preferred from Healthcare Industry Leaders To Commercialize Cancer Risk Stratification Services To Support Better Patient Insights And Outcomes appeared first on AiThority.mushroom investors funding research